» Articles » PMID: 28627984

Diagnostic Accuracy of Proton Magnetic Resonance Spectroscopy and Perfusion-weighted Imaging in Brain Gliomas Follow-up: a Single Institutional Experience

Overview
Journal Neuroradiol J
Publisher Sage Publications
Specialties Neurology
Radiology
Date 2017 Jun 20
PMID 28627984
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives The objective of this study was to evaluate whether proton magnetic resonance spectroscopy and perfusion magnetic resonance imaging (MRI) are able to increase diagnostic accuracy in the follow-up of brain gliomas, identifying the progression of disease before it becomes evident in the standard MRI; also to evaluate which of the two techniques has the best diagnostic accuracy. Methods Eighty-three patients with cerebral glioma (50 high-grade gliomas (HGGs), 33 low-grade gliomas (LGGs)) were retrospectively enrolled. All patients underwent standard MRI, H spectroscopic and perfusion echo-planar imaging MRI. For spectroscopy variations of choline/creatine, choline/N-acetyl-aspartate ratio, and lipids and lactates peak were considered. For perfusion 2.0 was considered the cerebral blood volume cut-off for progression. The combination of functional parameters gave a multiparametric score (0-2) to predict outcome. Diagnostic performance was determined by the receiver operating characteristic curve, with sensitivity, specificity, positive predictive and negative predictive values. Results In patients with LGGs a combined score of at least 1 was the best predictor for progression (odds ratio (OR) 3.91) with 8.4 months median anticipation of diagnosis compared to standard MRI. The individual advanced magnetic resonance technique did not show a diagnostic accuracy comparable to the combination of the two. Overall diagnostic accuracy area under the curve (AUC) was 0.881. In patients with HGGs the multiparametric score did not improve diagnostic accuracy significantly. Perfusion MRI was the best predictor of progression (OR 3.65), with 6.7 months median anticipation of diagnosis. Overall diagnostic accuracy AUC was 0.897. Then spectroscopy and perfusion MRI are able to identify tumour progression during follow-up earlier than standard MRI. Conclusion In patients with LGGs the combination of the functional parameters seems to be the best method for diagnosis of progression. In patients with HGGs perfusion is the best diagnostic method.

Citing Articles

Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.

Morrow K, Sloan A, Olson J, Ormond D J Neurooncol. 2024; 171(1):105-130.

PMID: 39400661 DOI: 10.1007/s11060-024-04838-5.


Radiomics: The New Promise for Differentiating Progression, Recurrence, Pseudoprogression, and Radionecrosis in Glioma and Glioblastoma Multiforme.

Alizadeh M, Lomer N, Azami M, Khalafi M, Shobeiri P, Arab Bafrani M Cancers (Basel). 2023; 15(18).

PMID: 37760399 PMC: 10526457. DOI: 10.3390/cancers15184429.


Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.

Muller M, Winz O, Gutsche R, Leijenaar R, Kocher M, Lerche C J Neurooncol. 2022; 159(3):519-529.

PMID: 35852737 PMC: 9477932. DOI: 10.1007/s11060-022-04089-2.


Changes in metabolites in the brain of patients with fibromyalgia after treatment with an NMDA receptor antagonist.

Fayed N, Olivan B, Lopez Del Hoyo Y, Andres E, Perez-Yus M, Fayed A Neuroradiol J. 2019; 32(6):408-419.

PMID: 31215319 PMC: 6856999. DOI: 10.1177/1971400919857544.


Brainstem glioma: Prediction of histopathologic grade based on conventional MR imaging.

Moharamzad Y, Taheri M, Niaghi F, Shobeiri E Neuroradiol J. 2017; 31(1):10-17.

PMID: 29148317 PMC: 5789999. DOI: 10.1177/1971400917743099.

References
1.
Spampinato M, Smith J, Kwock L, Ewend M, Grimme J, Camacho D . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 2006; 188(1):204-12. DOI: 10.2214/AJR.05.1177. View

2.
Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

3.
Wong E, Brem S . Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007; 25(30):4705-6. DOI: 10.1200/JCO.2007.13.1037. View

4.
Scarabino T, Popolizio T, Trojsi F, Giannatempo G, Pollice S, Maggialetti N . Role of advanced MR imaging modalities in diagnosing cerebral gliomas. Radiol Med. 2008; 114(3):448-60. DOI: 10.1007/s11547-008-0351-9. View

5.
Roy B, Gupta R, Maudsley A, Awasthi R, Sheriff S, Gu M . Utility of multiparametric 3-T MRI for glioma characterization. Neuroradiology. 2013; 55(5):603-13. PMC: 4209475. DOI: 10.1007/s00234-013-1145-x. View